Active Filter(s):
Details:
Under the terms of the agreement, Neuramedy has obtained worldwide rights to research, develop and commercialize an xB3TM version of its antibody, Tomaralimab, directed at the Toll-like receptor 2.
Lead Product(s): Tomaralimab
Therapeutic Area: Neurology Product Name: NM-101
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Bioasis
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration May 10, 2022